The Fellow on Call: The Heme/Onc Podcast

This week, we round out our discussion on the early stage breast cancer, turning our attention to the triple negative subtype. Once again, there are a lot of trials and data, but be sure to check out the show notes for the highlights! Content: - What is TNBC?-What is the data to support the use of neoadjuvant therapy in this disease? - What is "pathologic CR" and how is different than "residual cancer burden"?- Can we ever omit neoadjuvant therapy?- What are our options for chemotherapy regimens in neoadjuvant and adjuvant setting? ** This episode has been sponsored by HemOnc.org** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

We continue on our journey through early stage breast cancer, this time turning our attention to HER2+ disease. There is a lot of data in this episode, as you will both hear and see. To make this easier, we highlight key takeaways to make understanding this even easier. Content: - What is HER2? - Discovery of trastuzumab- Data for use of trastuzumab in adjuvant and neoadjuvant setting- Data for use of pertuzumab in adjuvant and neoadjuvant setting - Data and use of trastuzumab emtansine (TDM-1) in the adjuvant setting- Management of HER2+ stage I breast cancer- Highlights of key trials that shape the paradigm of management- Our approach to management ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

This week’s episode is part 4 of 5 of a joint mini-series with our friends Two Onc Docs. In today’s episode, we will be recapping the current treatment of resectable NSCLC and discussing KEYNOTE 671, which was presented at ASCO 2023, looking at neoadjuvant chemo+immunotherapy followed by adjuvant immunotherapy. We also discuss the use of the “interaction test,” “multiplicity,” and it’s important role in understanding subgroup analyses. Content: - A quick recap of the current standard of care for resectable lung non-small cell lung cancer - A discussion about KEYNOTE 671 presented at ASCO 2023- We define the "interaction test"- We discuss "multiplicity"Want to read the abstract for yourself? Click here!Episode list: Episode 1 covering covering rectal cancer & the PROSPECT Trial, as well as non-inferiority trials (released by Two Onc Docs): https://podcasts.apple.com/us/podcast/updates-from-asco23-rectal-cancer-the-prospect-trial/id1616541733?i=1000616604349Episode 2 covering classical hodgkin’s lymphoma & SWOG 1826 as well as “p-values” and what it means when trials say “the median was not reached.” (released by The Fellow on Call): Episode 061: “Paging Heme/Onc: Updates from ASCO 2023” - Classical Hodgkin’s Lymphoma and SWOG 1826Episode 3 covering mRCC & the CONTACT03 Trial, as well as subgroup analysis (released by Two Onc Docs): https://podcasts.apple.com/us/podcast/updates-from-asco23-mrcc-the-contact03-trial/id1616541733?i=1000617519386** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

This week’s episode is part 2 of 5 of a joint mini-series with our friends Two Onc Docs. In today’s episode, we recap the current treatment of classical hodgkin’s lymphoma and then dive into the the SWOG 1826 plenary session abstract from the ASCO 2023 annual meeting. We also cover the concept of “p-values” and what it means when trials say “the median was not reached.” Content: - A quick recap of the current standard of care for classical hodgkin's lymphoma- A review of the recent SWOG 1826 trial presented at ASCO 2023- A discussion about "p-values"- A discussion about what it means when "the median was not reached" Want to reach the abstract yourself? Click here: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.17_suppl.LBA4?af=RHave you checked out Episode 1? See link here for this episode released by Two Onc Docs: https://podcasts.apple.com/us/podcast/updates-from-asco23-rectal-cancer-the-prospect-trial/id1616541733?i=1000616604349** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

We are taking a small pause from our breast cancer series to discuss an important topic that is so critical to understand for clinical practice, no matter what discipline of medicine you are in: the fundamentals of transfusion medicine. This topic often shows up quite frequently on board exams, as well. In this episode, we talk about terms such as “type and screen” and more. Content: - What is a "type and screen"?- What does this process entail? - What is the difference between this and crossmatching? - When do we see discrepancies in the antibody screen? ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Surprise! The teams at Two Onc Docs and The Fellow on Call are teaming up for his special series! Each episode will focus on a single abstract, poster, or oral presentation from ASCO 2023, and will feature a quick review of any guidelines and management pointers relevant to the disease state under study, followed by an overview of the study design and findings, and finally a discussion of the implications of the research on clinical practice.We expect to release episodes on June 12, 14, 19, 21, and 26. Episodes will be released alternating between our two podcasts, so make sure you’re subscribed to both!Follow Two Onc Docs on Twitter: www.twitter.com/twooncdocsSubscribe to Two Onc Docs on Apple Podcasts: https://podcasts.apple.com/us/podcast/two-onc-docs/id1616541733 Follow The Fellow on Call on Twitter: www.twitter.com/thefellowoncall Subscribe to The Fellow on Call on Apple Podcasts: https://podcasts.apple.com/us/podcast/the-fellow-on-call-the-heme-onc-podcast/id1602921628 Subscribe to The Fellow on Call on Spotify: https://open.spotify.com/show/3LFKY3jlU2T0MpvKwkvMvl?si=acca1fa9413a4f60&nd=1 Subscribe to The Fellow on Call on Google Podcasts: https://podcasts.google.com/search/the%20fellow%20on%20call

This week, we continue discussing the management of early stage ER+/HER2- breast cancer. If you have not done so already, be sure to check out Episode 057 for the first part of this discussion. Content: - Who warrants chemotherapy?- Who benefits from gene expression assays?- What are important gene expression assays used clinically?- Post-treatment surveillance and survivorship - Targeted agents in the adjuvant setting ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

After several weeks of incredible discussions with our special guests, it’s time that we dive into the medical oncology regarding breast cancer. We start our discussion with the first of our two-part discussion on early stage (AKA non-metastatic) ER+/HER2- breast cancer. Content:- What information do we need to consider in patients with HR+ breast cancer? -What is the role of chemotherapy? -If chemotherapy is indicated, what are the treatment options? Why?-Anti-estrogen therapy selection and duration -Is there a role in ovarian suppression in HR+ disease? ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

So much incredible progress has been made in the management and treatment of breast cancer, largely thanks to advances in available therapies and drugs. A good understanding of pharmacology is key to selecting the correct regimen and providing counseling to your patients. This week, are so fortunate to be joined by special guest Dr. Danielle Roman, PharmD, who is an Oncology Clinical Pharmacy Specialist at West Penn Allegheny Oncology Network in Pennsylvania, as she helps us navigate breast cancer pharmacology.Content:- A discussion about different anti-estrogen therapies - Counseling about anti-estrogen therapy side effects- An overview of regimens used in ER+, HER2+, triple negative disease - Highlighting key trials related to the approval of these agents - Supportive care for breast cancer patients ** This episode is sponsored by HemOnc.org!**Thank you to our guest, Dr. Danielle Roman** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Surgery plays a pivotal role in the management of breast cancer, particularly in early stages of disease. This week, we are joined by special guest Dr. Carla Fisher, Associate Professor and Medical Director of Breast Surgical Oncology at Indiana University School of MedicineContent:- When to perform breast conservation surgery - When is additional imaging required? - Timing of neoadjuvant/adjuvant therapy in relation to breast surgery - What is a sentinel lymph node biopsy? - A discussion about breast reconstruction surgery- When is prophylactic mastectomy performed? - Role of surgery in inflammatory breast cancer ** Thank you to our guest, Dr. Carla Fisher! **Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast